1 March 2017 - The U.S. FDA today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), in people 18 through 65 years of age.

The safety and efficacy of Odactra was evaluated in studies conducted in the United States, Canada and Europe, involving approximately 2,500 people. Some participants received Odactra, while others received a placebo pill. Participants reported their symptoms and the need to use symptom-relieving allergy medications. During treatment, participants taking Odactra experienced a 16 to 18% reduction in symptoms and the need for additional medications compared to those who received a placebo.

Read FDA press release